The Unraveling of British Business: Robert Wessman’s Decision to Leave the UK Over Tax Policies

As the spectre of political instability continues to cast a long shadow over the United Kingdom, Robert Wessman, an Icelandic billionaire and founder of the biopharmaceutical company Alvotech, has found himself at a crossroads. In a recent interview, Wessman expressed grave concerns regarding the UK’s tax environment, labelling it as “anti-wealth” and unwelcoming to both foreign and domestic investors. Since moving from Iceland to London in 2019, Wessman has watched the landscape transform in ways that have prompted him to reconsider his investments and residence in the UK.

The business magnate’s grievances stem primarily from the landscape shaped by inheritance and capital gains taxes, compounded by the uncertainty that has followed Brexit. Wessman, who has experienced the turbulent waters of global finance, points to this “whole package” as a significant deterrent to wealth retention and attraction in the UK. He states, “It’s just the whole scheme has changed so much, which makes it very difficult for not only foreigners to come here, but for wealthy people, who live here, are born here, and have always been here, to basically stay here.” His sentiments resonate with a growing number of affluent individuals who are becoming increasingly dissatisfied with the direction in which British policies are heading.

Wessman’s career trajectory paints a picture of resilience and ambition. He first garnered international attention as he spearheaded the transformation of Delta, a small Icelandic company, into Actavis, one of the world’s largest generic drug manufacturers. However, the journey was not without obstacles; Wessman faced setbacks during the Icelandic banking crisis of 2008, which cost him an estimated €250 million. Yet, his current venture, Alvotech, represents a fresh chapter in his long career, as he strives to carve out a significant foothold in the biosimilars market, a field of medicine that promises to offer affordable alternatives to complex biologics when patents expire.

Alvotech’s growing prominence is a reflection of Wessman’s sustained investment in innovation. With over $2 billion invested since its inception in 2013, the company has steadily expanded its operations, particularly in Iceland, where it has established a manufacturing and R&D base. Currently valued at around $1 billion and having generated revenues of $593 million last year, Alvotech is predicted to see revenues between $650 million and $700 million in 2026. This ambitious growth trajectory is indicative of both Wessman’s tenacity and the potential of the biosimilars market. Yet, amid this success, he finds himself at odds with the UK’s shifting political and economic landscape.

The ramifications of Brexit continue to echo throughout the business community, with Wessman underscoring that substantial disruption has left many firms hesitant to view the UK as a viable option for future investments. He remarked that even major banks have ceased considering the UK as a suitable listing venue for their operations. The fallout has triggered conversations about whether the UK is losing its status as a capital hub in light of changing regulations and policies. For Wessman, the uncertainty brought on by this seismic shift makes it untenable to commit significant resources to the UK, as the turbulent environment hinders his capacity to forecast future growth.

In light of this instability, Wessman has been drawn to explore opportunities in other countries. Recently, he visited Milan with an eye on potential property acquisitions, illustrating his intention to reposition himself and his business interests should the climate in the UK remain unfavourable. The sense of unease is palpable; as Wessman observes, mobility of capital allows wealthy individuals like him to consider alternative locations that offer greater investment certainty.

The exodus of British and foreign elites is no longer a hypothetical concern. According to recent analyses, the Sunday Times Rich List revealed that one in six individuals who appeared on the list two years ago are now absent, demonstrating a significant loss of high-net-worth individuals from the country. Furthermore, a noteworthy trend is emerging wherein nearly a third of the UK citizens listed among the wealthiest no longer reside on the British mainland. As Wessman succinctly summarised, “We are leaving with a lot of capital. We are leaving with a lot of jobs.”

This migration is more than a mere inconvenience; it presents a palpable threat to the very fabric of the UK’s economy. The talents and investments that wealthy individuals bring are increasingly being tempted away by nations that offer more predictable tax regimes and political stability. It is, of course, not solely Wessman who feels this way; his views reflect broader sentiments among his peers who are equally wary of the implications of being taxed without sufficient equity in return.

Wessman’s comments regarding the quality of life in London paint a contradictory picture. On the one hand, he praises the capital for its “world-class” education and cultural richness. Yet, on the other hand, these positives are severely undermined by the harsh realities of navigating an unpredictable fiscal landscape. He recalls his experience of relocating to London “against the stream when Brexit was happening” and how he once perceived it as a hub for international business. However, with the increasing turbulence around tax legislation and the lasting impact of Brexit, his optimism is waning. He insists that taxation must be balanced with a sense of certainty and scope; otherwise, the fabric of national interests will fray.

As a testament to his integral role in the UK’s business community, Wessman cites how his substantial contributions are not merely beneficial to his wealth but extend to improved systems for education, infrastructure, and healthcare. This raises questions about what the future holds for countries that neglect to stabilise their appeal to high-net-worth individuals. Wessman’s reflections highlight a critical juncture not just for himself but for myriad investors weighing the merits of maintaining their presence in the UK against better opportunities abroad.

Although Wessman has indicated an unwillingness to depart without due consideration, he is ultimately left pondering the larger implications of a climate in which political expediency often trumps business sensibility. He exclaims that the current political landscape in the UK is marked by ongoing uncertainty over what comes next, further igniting the concerns of restless capital which he believes will increasingly seek refuge elsewhere. Unfortunately, if the trend continues, Britain may soon find itself staring into an economic abyss, struggling to retain its hold on the business elite who have historically contributed to its wealth.

The case of Robert Wessman serves as a bellwether for the wider crisis facing the UK at this moment. As he stands on the precipice of potential departure, his narrative underscores the urgent need for policymakers to consider the economic repercussions of their legislative decisions. Whether the government is willing to listen to entrepreneurs like Wessman remains to be seen, but the stakes have never been higher for a nation now facing the realities of a rapidly changing global landscape.